Gilead Sciences | GILD - Marktkapitalisierung





Marktkapitalisierung Veränderung Datum
AbbVie USD 384.69B 19.14B 2026-03
Agios Pharmaceuticals USD 2.01B 423M 2026-03
ALKERMES USD 5.88B 1.26B 2026-03
Alnylam Pharmaceuticals USD 44.15B 8.39B 2026-03
Amgen USD 189.89B 13.64B 2026-03
Biogen USD 26.9B 1.09B 2026-03
BioMarin Pharmaceutical USD 10.86B 553M 2026-03
Bristol-Myers Squibb USD 123.83B 14.02B 2026-03
Coherus Biosciences USD 172M 19M 2025-12
Eli Lilly USD 869.02B 146.97B 2026-03
Gilead Sciences USD 172.99B 20.71B 2026-03
GlaxoSmithKline GBP 83.8B 9.44B 2026-03
Glaxosmithkline GBP 108.55B 736M 2026-07
Incyte USD 18.73B 660M 2026-03
J&J USD 579.15B 78.91B 2026-03
Merck USD 297.1B 35.84B 2026-03
Moderna USD 20.15B 8.53B 2026-03
Neurocrine Biosciences USD 13.25B 890M 2026-03
Novartis USD 307.76B 15.54B 2026-03
Pfizer USD 153.81B 12.24B 2026-03
PTC Therapeutics USD 5.64B 460M 2026-03
Regeneron Pharmaceuticals USD 81.68B 560M 2026-03
Sanofi EUR 100.27B 605.48M 2026-03
Sarepta Therapeutics USD 2.28B 30M 2026-03
United Therapeutics USD 25.19B 4.21B 2026-03
Vertex Pharmaceuticals USD 113.58B 1.44B 2026-03